News >

JNJ-4528 Boasts High Response Rate in Relapsed/Refractory Myeloma

Caroline Seymour
Published: Thursday, Feb 06, 2020

Deepu Madduri, MD

Deepu Madduri, MD

The anti-BCMA CAR T-cell therapy JNJ-4528 led to a 100% overall response rate (ORR) with a manageable toxicity profile in patients with heavily pretreated relapsed/refractory multiple myeloma, according to Deepu Madduri, MD, who added that ongoing research efforts will determine the durability of these responses.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication